CJC-1295
Animal / preclinicalWADA prohibitedAlso known as: with DAC, Mod GRF (1-29)
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A GHRH analogue that amplifies the body's natural GH pulses, classically paired with ipamorelin to hit both release pathways at once. Pharmacology studies show substantial, sustained GH and IGF-1 elevation, especially with the DAC variant; physique outcome trials are lacking.
Mechanism
Analogue of GHRH that stimulates pituitary GH release; the DAC modification extends half-life from hours to days for sustained elevation.
Evidence
Pharmacology data show marked GH/IGF-1 increases; no trials yet tie that elevation to measured physique outcomes.
Community-reported information
Community reports vary. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Days (DAC variant); shorter without DAC.
Storage
Refrigerate lyophilised and reconstituted.
Commonly reported side effects
- Flushing
- Water retention
- Injection-site reactions
Legal status by region
- USNot FDA-approved for human use.
- AUPrescription-only; import controlled.
Legal status changes over time; verify locally before relying on this.
Frequently asked questions
- What is the difference between CJC-1295 with and without DAC?
- The DAC (drug affinity complex) modification greatly extends half-life to days; without DAC (often called Mod GRF 1-29) it is much shorter-acting.
- Why is CJC-1295 combined with ipamorelin?
- They hit complementary GH-release pathways — a GHRH analogue amplifying the pulse and a ghrelin-receptor agonist triggering it — so the combination releases more GH than either alone, which is why it's the classic pairing. Note both are WADA-prohibited for tested athletes.